Search
Vecabrutinib
go.drugbank.com/drugs/DB16657InvestigationalVecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).
Phenprocoumon
go.drugbank.com/drugs/DB00946ApprovedInvestigationalWithdrawnCoumarin derivative that acts as a long-acting oral anticoagulant.
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexLerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigational[L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia … Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9).
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Categories: Dopamine D2 Receptor AntagonistsTrimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications … Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Phenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIngestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829] … Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during
Cethromycin
go.drugbank.com/drugs/DB06419Investigational[A203369] Since this time, cethromycin has received FDA orphan drug designations for the prophylactic treatment of anthrax inhalation, plague due to _Yersinia pestis_, and tularemia due to _Francisella … Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system.
Hydroxyethyl cellulose
go.drugbank.com/drugs/DB11602ApprovedIt is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature. … It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic
Salts: Hydroxyethyl cellulose (100 MPa.s at 2%), Hydroxyethyl cellulose (140 MPa.s at 5%)Categories: Compounds used in a research, industrial, or household setting